Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 5 for:    regn2477

Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04577820
Recruitment Status : Not yet recruiting
First Posted : October 8, 2020
Last Update Posted : February 11, 2021
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:

The primary safety objective of the study is to assess the safety and tolerability of garetosmab in Japanese male and female adult patients with FOP.

The primary efficacy objective of the study is to assess the effect of garetosmab on Heterotopic ossification (HO) in Japanese adult patients with FOP, as determined by the number of new heterotopic bone lesions identified by computed tomography (CT).


Condition or disease Intervention/treatment Phase
Fibrodyplasia Ossificans Progressiva (FOP) Heterotopic Ossification (HO) Drug: garetosmab Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva
Estimated Study Start Date : October 13, 2021
Estimated Primary Completion Date : March 1, 2022
Estimated Study Completion Date : October 8, 2022


Arm Intervention/treatment
Experimental: garetosmab Drug: garetosmab
Repeated doses administered intravenously (IV) every four weeks (Q4W)
Other Name: REGN2477




Primary Outcome Measures :
  1. Incidence and severity of treatment-emergent adverse event (TEAEs) [ Time Frame: Through week 28 ]
  2. Number of new HO lesions as assessed by CT [ Time Frame: At week 28 ]

Secondary Outcome Measures :
  1. Total volume of new HO lesions as assessed by CT [ Time Frame: At week 28 ]
  2. Number of new HO lesions as assessed by positron emission tomography (PET) [ Time Frame: At week 28 ]
  3. Total lesion activity in new HO lesions as assessed by PET [ Time Frame: At week 28 ]
  4. Percent of patients with new HO lesions as assessed by CT [ Time Frame: At week 28 ]
  5. Percent of patients with new HO lesions as assessed by PET [ Time Frame: At week 28 ]
  6. Percent of patients with investigator-assessed flare-ups [ Time Frame: Baseline to week 28 ]
  7. Percent of patients with investigator-assessed flare-ups [ Time Frame: Baseline to week 56 ]
  8. Percent of patients with flare-ups assessed by patient e-diary [ Time Frame: Baseline to week 28 ]
  9. Percent of patients with flare-ups assessed by patient e-diary [ Time Frame: Baseline to week 56 ]
  10. Number of new HO lesions as assessed by CT [ Time Frame: At week 56 ]
  11. Total volume of new HO lesions as assessed by CT [ Time Frame: At week 56 ]
  12. Percent of patients with new HO lesions as assessed by CT [ Time Frame: At week 56 ]
  13. Number of new HO lesions as assessed by PET [ Time Frame: At week 56 ]
  14. Total lesion activity in new HO lesions as assessed by PET [ Time Frame: At week 56 ]
  15. Percent of patients with new HO lesions as assessed by PET [ Time Frame: At week 56 ]
  16. Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET [ Time Frame: Baseline and week 28 ]
  17. Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET [ Time Frame: Baseline and week 56 ]
  18. Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET [ Time Frame: Baseline and week 28 ]
  19. Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET [ Time Frame: Baseline and week 56 ]
  20. Change in total lesion activity by PET [ Time Frame: Baseline and week 28 ]
  21. Change in total lesion activity by PET [ Time Frame: Baseline and week 56 ]
  22. Percent change in total lesion activity by PET [ Time Frame: Baseline and week 28 ]
  23. Percent change in total lesion activity by PET [ Time Frame: Baseline and week 56 ]
  24. Change in the total volume of HO lesions as assessed by CT [ Time Frame: Baseline and week 28 ]
  25. Change in the total volume of HO lesions as assessed by CT [ Time Frame: Baseline and week 56 ]
  26. Percent change in the total volume of HO lesions as assessed by CT [ Time Frame: Baseline and week 28 ]
  27. Percent change in the total volume of HO lesions as assessed by CT [ Time Frame: Baseline and week 56 ]
  28. Change in number of HO lesions as assessed by PET [ Time Frame: Baseline and week 28 ]
    HO lesions defined as target and new lesions relative to baseline.

  29. Change in number of HO lesions as assessed by PET [ Time Frame: Baseline and week 56 ]
    Defined above

  30. Change in the number of HO lesions detectable by CT [ Time Frame: Baseline and week 28 ]
    Defined above

  31. Change in the number of HO lesions detectable by CT [ Time Frame: Baseline and week 56 ]
    Defined above

  32. Time-weighted average (standardized area under curve [AUC]) change in daily pain due to FOP, as measured using the daily numeric rating scale (NRS) [ Time Frame: Baseline through week 28 ]
    The NRS is a categorical rating scale used by patients to rate their pain associated with FOP. Patients will be asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain).

  33. Time-weighted average (standardized AUC) change in daily pain due to FOP, as measured using the daily NRS [ Time Frame: Baseline through week 56 ]
  34. Total dosage of glucocorticoids use [ Time Frame: Through week 56 ]
  35. Incidence and severity of TEAEs [ Time Frame: Through week 56 ]
  36. Concentration of total activin A in serum over time [ Time Frame: Through week 56 ]
  37. Pharmacokinetic (Pk) Profile - concentrations of garetosmab in serum over time [ Time Frame: Through week 56 ]
  38. Immunogenicity as measured by Anti-drug antibodies (ADA) to garetosmab over time [ Time Frame: Through week 28 ]
  39. Percent change from baseline in biomarkers of bone formation levels in serum [ Time Frame: Through week 28 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Clinical diagnosis of FOP (based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive HO)
  • Confirmation of FOP diagnosis with documentation of any Type I activin A receptor (ACVR1) mutation
  • FOP disease activity, as defined in the protocol, within 1 year of screening visit
  • Willing and able to undergo PET and CT imaging procedures and other procedures as defined in this study
  • Able to understand and complete study-related questionnaires and diaries (assistance from caregivers is allowed)

Key Exclusion Criteria:

  • Patient has significant concomitant illness or history of significant illness such as but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study
  • Previous history or diagnosis of cancer
  • Severely impaired renal function defined as estimated glomerular filtration rate <30 mL/min/1.73 m2 calculated by the Modification of Diet in Renal Disease equation (1 retest is allowed)
  • Uncontrolled diabetes defined as hemoglobin A1C (HbA1c) >9% at screening (1 retest allowed)
  • History of severe respiratory compromise, as defined in protocol
  • Concurrent participation in another interventional clinical study or a non-interventional study with radiographic measures or invasive procedures
  • Pregnant or breastfeeding women

NOTE: Other protocol defined inclusion/exclusion criteria apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04577820


Contacts
Layout table for location contacts
Contact: Clinical Trials Administrator 844-734-6643 clinicaltrials@regeneron.com

Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04577820    
Other Study ID Numbers: R2477-FOP-1940
First Posted: October 8, 2020    Key Record Dates
Last Update Posted: February 11, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access Criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Myositis Ossificans
Ossification, Heterotopic
Pathologic Processes
Myositis
Muscular Diseases
Musculoskeletal Diseases